How is the individualized dosage of Platinib determined?

Pralsetinib (Pralsetinib) is a kinase inhibitor primarily used to treat metastatic RET fusion-positive non-small cell lung cancer (NSCLC). It is also indicated for patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and are unresponsive to radioactive iodine therapy, when appropriate. The drug has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with NSCLC.

When determining the dosage of platinib, doctors will consider multiple factors of the patient, including weight, body surface area, age, gender, overall health, comorbidities, and drug interactions. For elderly patients, because their liver and kidney functions may be relatively weak, doctors may adjust the dose according to the situation. Prior to the use of platinib, the presence of the RET gene fusion must be determined in the patient's thyroid cancer or non-small cell lung cancer. This is critical to ensure patients benefit from treatment and avoid unnecessary drug use.

The usual dosage of Platinib is once daily, the dose is 400 mg. It is recommended to take it orally on an empty stomach, or avoid eating at least 2 hours before taking the medicine and at least 1 hour after taking the medicine. Patients should continue treatment until their condition worsens or drug toxicity becomes unacceptable. If adverse reactions occur, your doctor may recommend adjusting the dose of platinib. Typically, the first adjustment will be down to 300 mg per day, then to 200 mg per day if the problem persists, and then to 100 mg per day if that doesn't work. If patients cannot tolerate the 100 mg daily dose, then they should permanently discontinue platinib. The purpose of these adjustments is to ensure patient safety while maximizing therapeutic effectiveness.